95 related articles for article (PubMed ID: 17953364)
1. [Effect of lymphokine activated killer from umbilical blood on human ovarian cancer in nude mouse models].
He YD; Peng ZL; Liu SL; Wang H; Pan XL
Sichuan Da Xue Xue Bao Yi Xue Ban; 2007 Sep; 38(5):810-2. PubMed ID: 17953364
[TBL] [Abstract][Full Text] [Related]
2. [The rapid activation of human LAK cells and their inhibition on ovarian cancer at the advanced stage].
Song YF; Zhao YN; Li J
Zhonghua Fu Chan Ke Za Zhi; 1994 Jun; 29(6):332-5, 381. PubMed ID: 8001405
[TBL] [Abstract][Full Text] [Related]
3. [Effect of lymphokine-activated killer cells of head and neck tumors in vitro and in nude mice].
Duan DS
Zhonghua Er Bi Yan Hou Ke Za Zhi; 1993; 28(5):281-3, 314. PubMed ID: 8192930
[TBL] [Abstract][Full Text] [Related]
4. [Effects of lymphokine-activated killer cells and interleukin-2 on the ascites formation and the survival time of nude mice bearing human ovarian cancer cells].
Kikuchi Y; Oomori K; Miyauchi M; Kita T; Kuki E; Iwano I; Hirata J; Nagata I
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Dec; 41(12):1891-5. PubMed ID: 2592812
[TBL] [Abstract][Full Text] [Related]
5. Local adoptive immunotherapy of human head and neck cancer xenografts in nude mice with lymphokine-activated killer cells and interleukin 2.
Sacchi M; Snyderman CH; Heo DS; Johnson JT; d'Amico F; Herberman RB; Whiteside TL
Cancer Res; 1990 May; 50(10):3113-8. PubMed ID: 2334906
[TBL] [Abstract][Full Text] [Related]
6. Augmentation of cytotoxicity of lymphokine activated killer cells on ovarian tumor cells by various biological response modifiers.
Nio Y; Zighelboim J; Berek JS; Bonavida B
Anticancer Res; 1990; 10(2A):441-6. PubMed ID: 2346317
[TBL] [Abstract][Full Text] [Related]
7. [Studies on lymphokine-activated killer (LAK) cell: accumulation in tumor tissue and the therapeutic effects of adoptive immunotherapy].
Wakizaka Y
Hokkaido Igaku Zasshi; 1992 Jul; 67(4):475-87. PubMed ID: 1330859
[TBL] [Abstract][Full Text] [Related]
8. [The anti-pancreatic cancer efficacy of LAK cells mediated by YPC3 monoclonal antibody in vitro and in vivo].
Chen QK; Yuan SZ
Zhonghua Zhong Liu Za Zhi; 1994 Sep; 16(5):353-5. PubMed ID: 7895586
[TBL] [Abstract][Full Text] [Related]
9. Non-cytotoxic and sublethal paclitaxel treatment potentiates the sensitivity of cultured ovarian tumor SKOV-3 cells to lysis by lymphokine-activated killer cells.
Law KS; Chen HC; Liao SK
Anticancer Res; 2007; 27(2):841-50. PubMed ID: 17465210
[TBL] [Abstract][Full Text] [Related]
10. A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD16.
Weiner LM; Holmes M; Adams GP; LaCreta F; Watts P; Garcia de Palazzo I
Cancer Res; 1993 Jan; 53(1):94-100. PubMed ID: 8093231
[TBL] [Abstract][Full Text] [Related]
11. [Anti-human lung giant cell cancer (PG) effect of human LAK cells in vitro and in nude mice].
Deng HY
Zhonghua Zhong Liu Za Zhi; 1990 Jul; 12(4):258-60. PubMed ID: 2272258
[TBL] [Abstract][Full Text] [Related]
12. [Experimental expansion and antitumor effects of LAK cells from cancer patient's peripheral blood].
Zhang BX
Zhonghua Zhong Liu Za Zhi; 1992 Jul; 14(4):253-6. PubMed ID: 1396072
[TBL] [Abstract][Full Text] [Related]
13. [Effect of LAK cells and BRM on the growth of pancreatic cancer cells injected into nude mice].
Asano H; Kobari M; Yusa T; Kawakami K; Matsuno S
Nihon Geka Gakkai Zasshi; 1994 Sep; 95(9):678-88. PubMed ID: 7838109
[TBL] [Abstract][Full Text] [Related]
14. Characterization of cord blood natural killer and lymphokine activated killer lymphocytes following ex vivo cellular engineering.
Ayello J; van de Ven C; Fortino W; Wade-Harris C; Satwani P; Baxi L; Simpson LL; Sanger W; Pickering D; Kurtzberg J; Cairo MS
Biol Blood Marrow Transplant; 2006 Jun; 12(6):608-22. PubMed ID: 16737934
[TBL] [Abstract][Full Text] [Related]
15. Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy.
Ayello J; van de Ven C; Cairo E; Hochberg J; Baxi L; Satwani P; Cairo MS
Exp Hematol; 2009 Oct; 37(10):1216-29. PubMed ID: 19638292
[TBL] [Abstract][Full Text] [Related]
16. Adoptive immunotherapy of human pancreatic cancer with lymphokine-activated killer cells and interleukin-2 in a nude mouse model.
Marincola FM; Da Pozzo LF; Drucker BJ; Holder WD
Surgery; 1990 Nov; 108(5):919-29. PubMed ID: 2237773
[TBL] [Abstract][Full Text] [Related]
17. [Antitumor effect of endothelial progenitor cells with TRAIL gene transfection on ovarian carcinoma xenografts in nude mice].
Zhou L; Yan MX; Yao M; Feng YJ
Ai Zheng; 2005 Nov; 24(11):1312-6. PubMed ID: 16552954
[TBL] [Abstract][Full Text] [Related]
18. Tumor growth suppression by a mouse/human chimeric anti-CEA antibody and lymphokine-activated killer cells in vitro and in SCID mouse xenograft model.
Senba T; Kuroki M; Arakawa F; Yamamoto T; Kuwahara M; Haruno M; Ikeda S; Matsuoka Y
Anticancer Res; 1998; 18(1A):17-24. PubMed ID: 9568050
[TBL] [Abstract][Full Text] [Related]
19. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
[TBL] [Abstract][Full Text] [Related]
20. [Lymphokine-activated killer cell induced from cord blood].
Wang YF; Jiang S
Zhonghua Fu Chan Ke Za Zhi; 1994 Feb; 29(2):78-81, 122-3. PubMed ID: 8033630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
